Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Neoadjuvant immunochemotherapy is expected to become the standard treatment mode for locally advanced esophageal squamous cell carcinoma (ESCC). This study aims to analyze the clinical outcomes and long-term survival of neoadjuvant immunochemotherapy for locally advanced ESCC, and explore the feasibility of using major pathological response (MPR) as a surrogate endpoint.
Methods: This real-world retrospective study consecutively included eligible patients with stage II-IVA locally advanced ESCC who received neoadjuvant immunochemotherapy and surgery between 2019 and 2022 at the Department of Thoracic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine.
Results: This study collected a total of 166 patients, and ultimately included 126 patients after screening. The objective response rate (ORR) was 69.8% (88/126). The incidence of grade 3-4 adverse events (AEs) was 13.5% (17/126). MPR was observed in 49 (38.9%) patients, and 24 (19.0%) patients achieved a complete pathological response (pCR). The median progression-free survival (PFS) was 31.7 months and the 3-year PFS rate was 56.3%. The median overall survival (OS) was not reached and the 3-year OS rate was 70.6%. The median PFS of the non-MPR group was 25.0 months, with the MPR group not achieved (hazard ratio [HR], 2.503; 95% CI 1.359-4.610; P = 0.0022). The median OS in the non-MPR group was 31.7 months and not reached in the MPR group (HR, 3.607; 95% CI 1.576-8.254; P = 0.0012). MPR is an independent prognostic factor affecting OS (HR, 2.522; 95% CI 1.018-6.401; P = 0.046).
Conclusions: Neoadjuvant immunochemotherapy is safe and effective for locally advanced ESCC, and can result in certain survival benefits. MPR can serve as a surrogate endpoint for predicting long-term OS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038973 | PMC |
| http://dx.doi.org/10.1186/s40001-025-02599-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of the safety and efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy in the treatment of locally advanced resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis based on four randomized controlled trials.
Front Oncol
August 2025
Department of Thoracic Surgery, North Sichuan Medical College Affiliated Hospital, Nanchong, Sichuan, China.
Background: Esophageal cancer is a leading type of cancer globally. Most patients diagnosed with esophageal cancer present at a locally advanced stage, for which the standard treatment paradigm involves a multimodal approach combining neoadjuvant therapy with surgical resection. However, even under this regimen, 30%-40% of patients develop distant metastases postoperatively.
View Article and Find Full Text PDFLetter to editor: Multichannel deep learning prediction of major pathological response after neoadjuvant immunochemotherapy in lung cancer: a multicenter diagnostic study.
Int J Surg
August 2025
Thoracic and Cardiovascular surgery, The First Affiliated Hospital of Hebei North University.
Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy.
Front Immunol
August 2025
Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Hangzhou, China.
Purpose: In this research, we established, for the first time, an immune-inflammatory prognostic score (IIPS) reflecting the balance of immune and inflammatory status to explore its prognostic value in patients with esophageal squamous cell carcinoma (ESCC) receiving neoadjuvant immunochemotherapy (NICT).
Methods: In this retrospective study, two hundred and five ESCC patients who received NICT were included. To ascertain whether IIPS was superior to other traditional immune-inflammatory indices (IIIs), we compared their predictive values.
Prognostic value of coagulation markers in locally advanced gastric cancer following neoadjuvant immunochemotherapy.
World J Gastrointest Oncol
August 2025
Department of Medicine, Apex Institute of Medical Science, Kolkata 700075, West Bengal, India.
Gastric cancer (GC) has remained one of the leading causes of cancer-related deaths globally. The development of noninvasive biomarkers in cancer diagnosis and treatment has gained substantial traction in recent years. Recent evidence highlights hypercoagulation as a promising prognostic biomarker, particularly in locally advanced GC (LAGC) who underwent radical resection after neoadjuvant immunochemotherapy (NICT).
View Article and Find Full Text PDFDevelopment and validation of a postoperative risk model for esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.
Front Med (Lausanne)
August 2025
Department of Thoracic Surgery, Gaozhou People's Hospital, Gaozhou, China.
Background: Esophageal squamous cell carcinoma (ESCC) remains a highly aggressive malignancy with a significant risk of recurrence, even after curative treatment. While neoadjuvant immunochemotherapy (nICT) combined with minimally invasive esophagectomy (MIE) has shown promise in improving outcomes for patients with locally advanced, resectable ESCC, the factors contributing to early postoperative recurrence remain unclear. This study aims to identify high-risk factors for short-term recurrence and develop a predictive model for recurrence in patients with locally advanced, resectable ESCC treated with nICT followed by MIE (McKeown approach).
View Article and Find Full Text PDF